This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
PNC-27 (30 mg Vial)
PNC-27 is a synthetic 32aminoacid peptide containing an HDM2binding domain linked to a membranepenetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3].
Quick Reference
What is PNC-27?
Research overview based on the cited scientific literature.
• Goal: Educational exploration of a p53derived peptide studied preclinically for selective cancercell membrane disruption[1][2].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality[5].
• Lyophilized: Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; shortterm refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is PNC-27 studied?
PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membranepenetrating leader sequence[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration[4]. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.
What does the research report about PNC-27?
Observations from preclinical literature only—no human data available.
• Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM2 while sparing normal cells[2][6].
• Mechanism involves direct membrane lysis rather than apoptosis in affected cells[7].
• No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established[3].
• Possible injectionsite reactions (redness, irritation) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on PNC-27?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
